CenterBook Partners LP Acquires 14,835 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

CenterBook Partners LP grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 125.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,654 shares of the medical research company's stock after acquiring an additional 14,835 shares during the quarter. CenterBook Partners LP owned 0.10% of Bio-Rad Laboratories worth $6,492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. GeoWealth Management LLC lifted its position in shares of Bio-Rad Laboratories by 342.9% during the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Picton Mahoney Asset Management lifted its position in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares in the last quarter. Curat Global LLC purchased a new position in shares of Bio-Rad Laboratories in the 1st quarter worth approximately $34,000. Allworth Financial LP boosted its stake in shares of Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after buying an additional 104 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Bio-Rad Laboratories by 2,928.6% in the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock valued at $70,000 after acquiring an additional 205 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

BIO traded down $0.09 during trading on Wednesday, reaching $247.26. The stock had a trading volume of 208,012 shares, compared to its average volume of 305,064. The stock has a market cap of $6.73 billion, a PE ratio of -3.24 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.43 and a current ratio of 5.99. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99. The business has a 50-day moving average of $237.97 and a 200-day moving average of $267.88.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The firm had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same period last year, the firm posted $2.30 earnings per share. The business's revenue was down 4.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on BIO. Citigroup cut their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Royal Bank Of Canada cut their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. UBS Group reduced their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Finally, Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Sunday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.